CO7170167A2 - N-[4-(quinolin-4 iloxi) ciclohexil(metil)](he-,te-,ro)aril-,carboxamidas como antagonistas del receptor de andrógenos, su producción y usos como productos medicinales - Google Patents

N-[4-(quinolin-4 iloxi) ciclohexil(metil)](he-,te-,ro)aril-,carboxamidas como antagonistas del receptor de andrógenos, su producción y usos como productos medicinales

Info

Publication number
CO7170167A2
CO7170167A2 CO14279115A CO14279115A CO7170167A2 CO 7170167 A2 CO7170167 A2 CO 7170167A2 CO 14279115 A CO14279115 A CO 14279115A CO 14279115 A CO14279115 A CO 14279115A CO 7170167 A2 CO7170167 A2 CO 7170167A2
Authority
CO
Colombia
Prior art keywords
quinolin
yloxy
cyclohexyl
methyl
production
Prior art date
Application number
CO14279115A
Other languages
English (en)
Inventor
Duy Nguyen
Hermann Kunzer
Gimenez Hortensia Faus
Benjamin Bader
Silke Kohr
Martin Fritsch
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48699019&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO7170167(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CO7170167A2 publication Critical patent/CO7170167A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/22Oxygen atoms attached in position 2 or 4
    • C07D215/233Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28Antiandrogens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se relaciona con N-(4-(quinolin-4-iloxi)ciclohexil(metil)] (hetero)arilcarboxamidas, intermediarios y métodos para su producción, uso de las mismas para tratar y/o prevenir enfermedades y uso de las mismas para producir productos medicinales y uso de los mismos para tratar y/o prevenir enfermedades, en especial enfermedades hiperproliferativas.
CO14279115A 2012-06-26 2014-12-19 N-[4-(quinolin-4 iloxi) ciclohexil(metil)](he-,te-,ro)aril-,carboxamidas como antagonistas del receptor de andrógenos, su producción y usos como productos medicinales CO7170167A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12004764 2012-06-26

Publications (1)

Publication Number Publication Date
CO7170167A2 true CO7170167A2 (es) 2015-01-28

Family

ID=48699019

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14279115A CO7170167A2 (es) 2012-06-26 2014-12-19 N-[4-(quinolin-4 iloxi) ciclohexil(metil)](he-,te-,ro)aril-,carboxamidas como antagonistas del receptor de andrógenos, su producción y usos como productos medicinales

Country Status (41)

Country Link
US (1) US9428460B2 (es)
EP (1) EP2864291B1 (es)
JP (1) JP6181172B2 (es)
KR (1) KR20150023880A (es)
AP (1) AP3919A (es)
AR (1) AR091565A1 (es)
AU (1) AU2013283543B2 (es)
BR (1) BR112014032538A2 (es)
CA (1) CA2877786C (es)
CL (1) CL2014003443A1 (es)
CO (1) CO7170167A2 (es)
CR (1) CR20140593A (es)
CU (1) CU20140144A7 (es)
CY (1) CY1118412T1 (es)
DK (1) DK2864291T3 (es)
DO (1) DOP2014000295A (es)
EA (1) EA028063B1 (es)
EC (1) ECSP14032516A (es)
ES (1) ES2609455T3 (es)
HK (1) HK1206346A1 (es)
HR (1) HRP20161745T1 (es)
HU (1) HUE032306T2 (es)
IL (1) IL236146B (es)
JO (1) JO3342B1 (es)
LT (1) LT2864291T (es)
MA (1) MA37700B1 (es)
ME (1) ME02590B (es)
MX (1) MX2014016054A (es)
NZ (1) NZ703100A (es)
PE (1) PE20150154A1 (es)
PH (1) PH12014502869A1 (es)
PL (1) PL2864291T3 (es)
PT (1) PT2864291T (es)
RS (1) RS55500B1 (es)
SG (1) SG11201408254UA (es)
SI (1) SI2864291T1 (es)
TN (1) TN2014000532A1 (es)
TW (1) TWI600646B (es)
UA (1) UA115447C2 (es)
UY (1) UY34881A (es)
WO (1) WO2014001247A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106413715A (zh) * 2014-04-22 2017-02-15 林伯士艾瑞斯公司 Irak抑制剂和其用途
UY36391A (es) * 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
KR20190003686A (ko) * 2016-05-04 2019-01-09 브리스톨-마이어스 스큅 컴퍼니 인돌아민 2,3-디옥시게나제의 억제제 및 그의 사용 방법
JP2019516687A (ja) * 2016-05-04 2019-06-20 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company インドールアミン2,3−ジオキシゲナーゼ阻害剤およびその使用方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5328821A (en) 1991-12-12 1994-07-12 Robyn Fisher Cold and cryo-preservation methods for human tissue slices
US6566372B1 (en) * 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
EP1296953A2 (en) 2000-06-23 2003-04-02 Eli Lilly And Company Methods and compounds for inhibiting mrp1
EP2088141A3 (en) 2001-06-22 2009-11-18 Kirin Pharma Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives capable of inhibiting autophosphorylation of hepatocyte growth factor receptors, and pharmaceutical composition comprising the same
AU2003261974A1 (en) 2002-09-11 2004-04-30 Kureha Chemical Industry Company, Limited Amine compounds and use thereof
US20050227932A1 (en) 2002-11-13 2005-10-13 Tianbao Lu Combinational therapy involving a small molecule inhibitor of the MDM2: p53 interaction
US20040242613A1 (en) 2003-01-30 2004-12-02 Boehringer Ingelheim Pharmaceuticals, Inc. Pyrimidine derivatives useful as inhibitors of PKC-theta
SE0302573D0 (sv) 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
WO2005094251A2 (en) 2004-03-17 2005-10-13 Glaxo Group Limited M3muscarinic acetylcholine receptor antagonists
SE0401342D0 (sv) 2004-05-25 2004-05-25 Astrazeneca Ab Therapeutic compounds
WO2005117570A1 (en) 2004-05-27 2005-12-15 Jack Saffron Feeding dish to prevent pest infestation
JP2008519761A (ja) 2004-11-09 2008-06-12 スミスクライン ビーチャム コーポレーション グリコーゲンホスホリラーゼ阻害化合物およびその医薬組成物
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
GB0509224D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Inhibitors of intracellular enzymatic activity
GB0509227D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Intracellular enzyme inhibitors
US20060293341A1 (en) 2005-06-23 2006-12-28 Vrej Jubian Alkyl sulfonamide derivatives
EP1981492A1 (en) 2006-02-06 2008-10-22 Showa Denko K.K. Whitening dermatological preparations
JP2009539878A (ja) 2006-06-08 2009-11-19 アレイ バイオファーマ、インコーポレイテッド キノリン化合物および使用方法
GB0619753D0 (en) 2006-10-06 2006-11-15 Chroma Therapeutics Ltd Enzyme inhibitors
WO2008064432A1 (en) 2006-12-01 2008-06-05 The University Of Sydney Polycyclic molecular compounds
EP2188277B1 (en) 2007-08-16 2012-11-21 Boehringer Ingelheim International GmbH Quinazolinedione chymase inhibitors
JP5535925B2 (ja) * 2007-10-26 2014-07-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア アンドロゲン受容体調節物質としてのジアリールヒダントイン化合物
US20110104161A1 (en) 2008-05-14 2011-05-05 Burgess Teresa L Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer
US20110229469A1 (en) 2008-10-01 2011-09-22 Ludwig Institute For Cancer Research Methods for the treatment of cancer
CN102471327A (zh) 2009-07-21 2012-05-23 吉里德科学公司 黄病毒科病毒的抑制剂
US20120238533A1 (en) 2009-09-11 2012-09-20 Bayer Pharma Aktiengesellschaft (Heteroarylmethyl) Thiohydantoins as anticancer drugs
US9050334B2 (en) 2010-07-16 2015-06-09 Innov88 Llc MIF inhibitors and their uses

Also Published As

Publication number Publication date
MA37700B1 (fr) 2018-03-30
KR20150023880A (ko) 2015-03-05
MA20150269A1 (fr) 2015-08-31
SI2864291T1 (sl) 2017-01-31
ES2609455T3 (es) 2017-04-20
AU2013283543B2 (en) 2017-11-02
CU20140144A7 (es) 2015-08-27
PL2864291T3 (pl) 2017-07-31
IL236146B (en) 2018-05-31
HK1206346A1 (en) 2016-01-08
TWI600646B (zh) 2017-10-01
DOP2014000295A (es) 2015-01-31
JO3342B1 (ar) 2019-03-13
AP3919A (en) 2016-11-30
DK2864291T3 (en) 2017-01-16
ME02590B (me) 2017-06-20
CA2877786A1 (en) 2014-01-03
PE20150154A1 (es) 2015-02-19
BR112014032538A2 (pt) 2017-06-27
EP2864291B1 (en) 2016-10-05
MX2014016054A (es) 2015-04-10
EA201500039A1 (ru) 2015-06-30
UA115447C2 (uk) 2017-11-10
AU2013283543A1 (en) 2015-01-29
CA2877786C (en) 2020-08-25
PH12014502869B1 (en) 2015-02-23
US9428460B2 (en) 2016-08-30
TN2014000532A1 (en) 2016-03-30
CL2014003443A1 (es) 2015-06-26
EA028063B1 (ru) 2017-10-31
WO2014001247A1 (en) 2014-01-03
AR091565A1 (es) 2015-02-11
RS55500B1 (sr) 2017-05-31
NZ703100A (en) 2016-10-28
JP6181172B2 (ja) 2017-08-16
PT2864291T (pt) 2017-01-06
HRP20161745T1 (hr) 2017-02-24
US20150191431A1 (en) 2015-07-09
AP2014008141A0 (en) 2014-12-31
TW201400460A (zh) 2014-01-01
ECSP14032516A (es) 2015-12-31
EP2864291A1 (en) 2015-04-29
IL236146A0 (en) 2015-02-01
LT2864291T (lt) 2017-01-10
CY1118412T1 (el) 2017-06-28
CN104684896A (zh) 2015-06-03
HUE032306T2 (en) 2017-09-28
CR20140593A (es) 2015-02-16
UY34881A (es) 2014-01-31
JP2015521641A (ja) 2015-07-30
SG11201408254UA (en) 2015-01-29
PH12014502869A1 (en) 2015-02-23

Similar Documents

Publication Publication Date Title
EA201591087A1 (ru) Новые производные бензимидазола в качестве антагонистов рецептора ep4
CL2014003165A1 (es) Proceso mejorado para la preparación de treprostinil y derivados del mismo.
EA201690246A1 (ru) Ингибиторы аутотаксинов, содержащие ядро гетероароматическое кольцо-бензил-амидный цикл
EA201591648A1 (ru) Бензимидазол-2-ил-пиримидиновые модуляторы рецептора гистамина h4
UY34603A (es) Anticuerpos anti-asic-1 y usos de los mismos
UY34725A (es) Nuevos derivados de tienopirimidina, procesos para su preparación y sus usos terapéuticos.
CO7170167A2 (es) N-[4-(quinolin-4 iloxi) ciclohexil(metil)](he-,te-,ro)aril-,carboxamidas como antagonistas del receptor de andrógenos, su producción y usos como productos medicinales
ECSP14002542A (es) Nuevos 2h–indazoles como antagonistas del receptor ep2
FI20126067A (fi) Menetelmä ja laitteisto jätteeksi luokiteltavan aineen käsittelemiseksi, menetelmällä valmistettu tuote ja tuotteen käyttö
CO6870030A2 (es) Nuevo proceso para la síntesis de 7-cloro-4-(piperazin-1-il)-quinolina
CL2016001495A1 (es) Espiro-oxazolonas.
UY35958A (es) Derivados de quinolina como insecticidas y acaricidas
FI20125946A (fi) Menetelmä ja laitteisto jätteeksi luokiteltavan aineen käsittelemiseksi, menetelmällä valmistettu tuote ja tuotteen käyttö
CO6930059A1 (es) Formulaciones farmacéuticas y proceso de producción de formulaciones farmacéuticas
FR3000392B1 (fr) Nouvelles compositions pharmaceutiques veterinaires et leur procede de preparation
TH1401007761A (th) N-[4-(ควิโนลิน-4-อิลอกซี)ไซโคลเฮกซิล(เมธิล)](เฮเทอโร)อะริลคาร์บอกซาไมด์ ในฐานะเป็นแอนโดรเจน รีเซฟเตอร์ แอนตาโกนิสท์, การผลิต และ การใช้ของสิ่งเหล่านั้นในฐานะเป็นผลิตภัณฑ์ซึ่งมีคุณสมบัติเป็นยา
UY34703A (es) Ciclobutilcarboxamidas, proceso para su preparación, composiciones pesticidas y composiciones farmacéuticas que las comprenden, y usos de las mismas como nematicidas
MA37780A1 (fr) Nouveaux acides 5-aminotétrahydrochinolino-2-carboxyliques et leur utilisation
ES2421810R1 (es) Intermedios utiles para la sintesis de fexofenadina, procedimientos para su preparacion y para la preparacion de fexofenadina
UY4420U (es) Pañal para adulto
UY4423U (es) Pañal para adulto
TH1401003731A (th) กระบวนการสำหรับการผลิตของ 1,3-บิวทาไดอีน